Intravitreal Bevacizumab (Avatin®) in the Treatment of Neovacular Glaucoma

Purpoe To decribe a cae erie of neovacular glaucoma (NVG) caued by central retinal vein occluion (CRVO) that wa treated with intravitreal bevacizumab (IVB; Avatin®). Deign Retropective interventional cae erie. Method ix conecutive patient with NVG and a refractory, ymptomatic elevation of intraocular preure (IOP) and pronounced anterior egment congetion received IVB (1.25 mg/0.05 ml). Diode laer cyclophotocoagulation wa carried out only if preure wa controlled inufficiently by topical medication. Follow-up examination occurred at four to 16 week. Reult IVB reulted in a marked regreion of anterior egment neovacularization and relief of ymptom within 48 hour. IOP decreaed ubtantially in three eye; in the other three eye, adjuvant cyclophotocoagulation wa neceary. No ide effect were oberved. Panretinal photocoagulation (PRP) wa performed a oon a feaible, five to 12 week after IVB treatment. Concluion IVB lead to a rapid regreion of iri and angle neovacularization and hould be invetigated more thoroughly a an adjunct in the management of NVG.